Trial Profile
A Prospective, Randomized, Double Blind, Parallel Group Study to Evaluate a 1:1 Dose Conversion From EPREX to EPIAO in Term of Clinical Efficacy and Safety in Subjects With End-Stage Renal Disease on Haemodialysis
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 03 Nov 2016
At a glance
- Drugs Recombinant erythropoietin (Primary) ; Epoetin alfa
- Indications Renal failure
- Focus Therapeutic Use
- Acronyms BEAT_002
- Sponsors Shenyang Sunshine Pharmaceutical
- 03 Nov 2016 New trial record